Prot #GS-US-592-6173 (ASCENT-04): A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic

Project: Research project

Project Details

StatusActive
Effective start/end date1/31/23 → 1/31/26

Funding

  • ICON Clinical Research Limited (Prot #GS-US-592-6173 // Prot #GS-US-592-6173)
  • Gilead Sciences, Inc (Prot #GS-US-592-6173 // Prot #GS-US-592-6173)